Abstract
Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Endpoint Determination
-
Humans
-
Lung Diseases, Interstitial / drug therapy
-
Lung Diseases, Interstitial / etiology*
-
Lung Diseases, Interstitial / physiopathology
-
Multicenter Studies as Topic
-
Randomized Controlled Trials as Topic / methods*
-
Research Design
-
Scleroderma, Systemic / complications*
-
Scleroderma, Systemic / drug therapy
-
Scleroderma, Systemic / physiopathology
-
Severity of Illness Index
-
Treatment Outcome
-
Vital Capacity